Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital ...

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central nervous system.

George Tidmarsh, who helmed the FDA’s Center for Drug Evaluation and Research, resigned Sunday following a complaint by biopharma investor Kevin Tang, whose affiliated company, Aurinia Pharmaceuticals ...

There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector system will be used, with AAV and lentivirus being two of the most commonly ...

With the shutdown ongoing, Evommune plans to close its IPO on Nov. 5 via a Securities Act clause that allows registrations to ...

But Doustdar also seems to recognize what he has in Novo Nordisk, the 100-year-old pharma that brought insulin to the masses, ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...

Bristol Myers Squibb beat analyst and consensus estimates for the third quarter with $12.2 billion in sales, but executives ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a ...